XML 45 R29.htm IDEA: XBRL DOCUMENT v3.22.0.1
Revenue Recognition and Accounts Receivable (Tables)
 12 Months Ended
Dec. 31, 2021
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue
The following table presents the Company’s net sales by product category for each of our reportable segments for the years ended December 31, 2021, 2020, and 2019, respectively:
(In millions)2021 Net Sales
Product CategoryDeveloped MarketsGreater ChinaJANZEmerging MarketsTotal
Brands5,759.2 2,207.8 1,197.1 1,677.2 10,841.3 
Complex Gx and Biosimilars1,241.6 0.2 46.5 53.8 1,342.1 
Generics3,427.9 4.8 783.8 1,413.7 5,630.2 
Total Viatris$10,428.7 $2,212.8 $2,027.4 $3,144.7 $17,813.6 

(In millions)2020 Net Sales
Product CategoryDeveloped MarketsGreater ChinaJANZEmerging MarketsTotal
Brands3,920.7 253.9 617.0 443.3 5,234.9 
Complex Gx and Biosimilars1,202.6 0.7 42.8 49.4 1,295.5 
Generics3,387.6 5.3 535.5 1,361.1 5,289.5 
Total Viatris$8,510.9 $259.9 $1,195.3 $1,853.8 $11,819.9 

(In millions)2019 Net Sales
Product CategoryDeveloped MarketsGreater ChinaJANZEmerging MarketsTotal
Brands4,199.1 207.6 533.3 422.1 5,362.1 
Complex Gx and Biosimilars1,127.4 0.4 23.8 59.7 1,211.3 
Generics2,913.5 6.6 635.4 1,241.4 4,796.9 
Total Viatris$8,240.0 $214.6 $1,192.5 $1,723.2 $11,370.3 

The following table presents net sales on a consolidated basis for select key products for the year ended December 31, 2021:
(In millions)Year Ended December 31, 2021
Select Key Global Products
Lipitor ®
$1,663.2 
Norvasc ®824.7 
Lyrica ®728.5 
Viagra ®533.8 
EpiPen® Auto-Injectors391.7 
Celebrex ®
344.4 
Effexor ®
316.8 
Creon ®309.8 
Zoloft ®
284.3 
Xalabrands226.0 
Select Key Segment Products
Influvac ®$299.3 
Amitiza ®201.5 
Xanax ®185.9 
Dymista ®168.0 
Yupelri ®161.9 
____________
(a)The Company does not disclose net sales for any products considered competitively sensitive.
(b)Products disclosed may change in future periods, including as a result of seasonality, competition or new product launches.
(c)Prior periods are not presented due to significance of products acquired as part of the Combination.
The following is a rollforward of the categories of variable consideration during 2021:
(In millions)Balance at December 31, 2020Current Provision Related to Sales Made in the Current Period Measurement Period Adjustments and ReclassesChecks/ Credits Issued to Third Parties Effects of Foreign ExchangeBalance at December 31, 2021
Chargebacks$585.2 $5,530.1 $63.4 $(5,585.4)$(1.6)$591.7 
Rebates, promotional programs and other sales allowances1,576.3 6,135.6 (57.6)(6,267.1)(14.2)1,373.0 
Returns539.9 384.6 269.0 (499.0)(7.7)686.8 
Governmental rebate programs313.3 689.5 110.6 (705.2)(9.0)399.2 
Total$3,014.7 $12,739.8 $385.4 $(13,056.7)$(32.5)$3,050.7 
Schedule of Accounts Receivable, Net Accounts receivable are presented net of allowances relating to these provisions, which were comprised of the following at December 31, 2021 and 2020, respectively:
(In millions)December 31,
2021		December 31,
2020
Accounts receivable, net$1,688.6 $1,802.9 
Other current liabilities1,362.1 1,211.8 
Total$3,050.7 $3,014.7